These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7516375)

  • 1. [Alfuzosin in the treatment of benign prostatic hypertrophy].
    Jardin A
    J Urol (Paris); 1993; 99(6):308-10. PubMed ID: 7516375
    [No Abstract]   [Full Text] [Related]  

  • 2. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Alfuzosin. A new selective alpha 1 receptor antagonist for symptomatic medical treatment of benign prostatic hypertrophy prior to surgery].
    Hansen BJ; Meyhoff HH
    Ugeskr Laeger; 1992 Feb; 154(6):361-2. PubMed ID: 1371629
    [No Abstract]   [Full Text] [Related]  

  • 4. [Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
    Fortschr Med Suppl; 1995; 166():1-12. PubMed ID: 7537599
    [No Abstract]   [Full Text] [Related]  

  • 5. [A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].
    Lopatkin NA; Perepanova TS
    Urol Nefrol (Mosk); 1997; (5):14-6. PubMed ID: 9412005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2004 Jan; 46(1173):1-2. PubMed ID: 14691408
    [No Abstract]   [Full Text] [Related]  

  • 7. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
    Schulman CC; De Sy W; Vandendris M; Tomas M; Santoni JP
    Acta Urol Belg; 1994 Dec; 62(4):15-21. PubMed ID: 7540794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
    Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
    Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alfuzosin for benign prostatic hypertrophy.
    Chapple CR
    Lancet; 1991 Jul; 338(8760):182. PubMed ID: 1712882
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
    McVary KT
    J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
    Tkachuk VN; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (2):38-40. PubMed ID: 9577703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)].
    Loran OB; Rasner PI; Kosko D; Pushkar' DIu
    Urologiia; 2001; (1):8-10. PubMed ID: 11233234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results with alpha-blockers in patients with symptomatic benign prostatic hyperplasia.
    Mensink HJ
    Prog Clin Biol Res; 1994; 386():285-9. PubMed ID: 7528396
    [No Abstract]   [Full Text] [Related]  

  • 16. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
    Lukacs B; Leplège A; Thibault P; Jardin A
    Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alfuzosin for benign prostatic hypertrophy.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Oct; 338(8772):947. PubMed ID: 1717801
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice].
    Lukacs B; Grange JC; Comet D; Mc Carthy C
    Prog Urol; 1999 Apr; 9(2):271-80. PubMed ID: 10370951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
    Armitage JN; Emberton M
    BJU Int; 2006 Mar; 97(3):439-41. PubMed ID: 16469003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.